Role of PET/CT in muscle-invasive bladder cancer

Transl Androl Urol. 2020 Dec;9(6):2908-2919. doi: 10.21037/tau.2020.03.31.

Abstract

The purpose of this study covered the diagnostic accuracy and usefulness of positron emission tomography/computed tomography (PET/CT) imaging in muscle invasive bladder cancer patients through previously published literature. Through 30 September, 2019, the PubMed database was searched for eligible articles that evaluated PET/CT imaging in bladder cancer patients. In general, FDG PET/CT, the most commonly used PET/CT imaging, does not show good performance for the detection of primary lesions; however, according to the literature it could accurately assess pelvic lymph node (LN) status better than other imaging technologies and it was especially helpful in determining extra-pelvic recurrences. More recently, non-FDG PET/CT imaging, such as C-11 acetate and C-11 choline, has been introduced. Although further research is required, preliminary results show the potential of these techniques to overcome the drawbacks of FDG. This concise study will overview the role of PET/CT when treating muscle-invasive bladder cancer (MIBC).

Keywords: C-11 acetate; C-11 choline; F-18 fluorodeoxyglucose; bladder cancer; lymph node (LN); positron emission tomography/computed tomography (PET/CT); restaging; staging.

Publication types

  • Review